Search Results
Sep 25, 2025, 06:30 ET AL-S Pharma Appoints Internationally Recognized Neurologist and Clinical Trial Expert Prof. Dr. Angela Genge as Chief Medical Officer
tolerability, pharmacodynamic (PD) markers, and pharmacokinetics (PK) of AP-101 in patients with sporadic ALS and patients with mutations in the SOD1 gene. About AL-S Pharma AGAL-S Pharma is a Swiss-based single-asset company founded and co-owned by Neurimmune and TVM Capital Life
More news about: AL-S Pharma AG
Sep 24, 2025, 16:51 ET Study Reveals How Tick-Borne Encephalitis Virus Enters Cells
targeted. Using a human cell line, they amassed a "library" of thousands of cell variants in which a different gene had been deleted; the variants were then exposed to TBEV. Only cell types lacking a gene necessary for TBEV infection should survive virus exposure. Unmasking the Culprit As
More news about: Albert Einstein College of Medicine
Sep 24, 2025, 14:13 ET Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation
development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy,
More news about: Hamlet BioPharma AB
Sep 24, 2025, 14:06 ET Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation
development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy,
More news about: Hamlet BioPharma AB
Sep 24, 2025, 11:13 ET Children's Hospital of Philadelphia Researchers Find Combination of Diet and Medication Reprograms Fatal Childhood Tumors
and his team used a preclinical model to mimic MYCN-driven neuroblastoma, directly addressing the strong association between extra MYCN gene copies and aggressive neuroblastoma with poor prognosis. Animal models with tumors were divided into groups: one fed a normal diet and the other lacking
More news about: Children's Hospital of Philadelphia
Sep 24, 2025, 10:59 ET ENCELTO Now Available Through OCLI Vision to Address Rare Retinal Disease, Announces Spectrum Vision Partners
practice managed by Spectrum Vision Partners, made medical history on September 22, 2025, by performing the first ENCELTO gene therapy procedure in the Northeast United States. This landmark achievement marked only the second commercial implantation
More news about: Spectrum Vision Partners
Sep 24, 2025, 10:00 ET The RI Life Science Hub Announces Foundational Members of Ocean State Labs, the State's First Life Science Incubator
Pax Therapeutics, advancing gene-delivery technologies to optimize healing of tendon and ligament injuries.
More news about: Rhode Island Life Science Hub
Sep 24, 2025, 09:31 ET ResVita Bio Announces Positive FDA Pre-IND Meeting, Advancing RVB-003 Toward IND Filing for Netherton Syndrome in Early 2026
Netherton Syndrome (NS) is caused by mutations in the SPINK5 gene, leading to uncontrolled protease activity, chronic skin inflammation, and life-threatening barrier defects. Patients face high morbidity and mortality,
More news about: ResVita Bio
Sep 24, 2025, 09:00 ET Hood College Receives NSF Grant for Biotechnology Training Program
the bioscience industry," said Rana Khan, inaugural director of BREC. "Focused on cutting-edge technologies in gene therapy and biomanufacturing, this funding will provide hands-on training and paid internships for our students while strengthening industry partnerships
More news about: Hood College
Sep 24, 2025, 02:45 ET New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies
sustained efficacy and a consistent safety profile for people with RMS," said Norman Putzki, M.D., Ph.D., Global Head Development, Neuroscience & Gene Therapy, Novartis. "These findings reinforce Kesimpta's position as a therapy that empowers patients to take early control of their disease."
More news about: Novartis Pharmaceuticals Corporation
Sep 23, 2025, 21:19 ET Mindray stellt auf der ISUOG „Project 2030" vor und schreibt Zukunft des Ultraschalls in der Frauenheilkunde neu
100 Artikeln – das ist die beeindruckende Bilanz des „Project 2025". Von nun an wird Mindray das „Project 2030" weiter umsetzen. Gene Liang, General Manager, Medical Imaging von Mindray, betonte: „Unser Ziel ist es, kontinuierlich zur Entwicklung einer Ultraschall-Grundausbildung
More news about: Mindray
Sep 23, 2025, 19:10 ET Mindray dévoile le Projet 2030 et réécrit l'avenir de l'échographie pour la santé des femmes à l'ISUOG
100 articles : telles sont les empreintes du Projet 2025. À l'avenir, Mindray continuera à mettre en œuvre le Projet 2030. Gene Liang, directeur général de l'imagerie médicale chez Mindray, a souligné : « Nous souhaitons contribuer sans cesse au développement de l'enseignement
More news about: Mindray
Sep 23, 2025, 12:08 ET LifeSpan Portfolio Company Remedium Signs Landmark Deal with Eli Lilly
("Remedium"), has entered into a multi-target research and development collaboration with Eli Lilly and Company ("Lilly") focused on advancing innovative gene therapies for Type 2 diabetes and obesity.
More news about: LifeSpan Vision Ventures
Sep 23, 2025, 12:06 ET Partillion's Nanovials Power Breakthrough Cell-Cell Interaction Mapping, Driving Call for Billion Cell × Cell Project
interaction-induced gene expression of single-cell pairs. "Current tools tell us what a cell is or where it resides, but not how it responds when it meets another cell. With Cell-Cell Seq, we finally capture how cells change each other over time by directly measuring the gene expression programs triggered
More news about: Partillion Bioscience
Sep 23, 2025, 11:39 ET LifeSpan Portfolio Company Remedium Signs Landmark Deal with Eli Lilly
("Remedium"), has entered into a multi-target research and development collaboration with Eli Lilly and Company ("Lilly") focused on advancing innovative gene therapies for Type 2 diabetes and obesity.
More news about: LifeSpan Vision Ventures
Sep 23, 2025, 09:23 ET AccuWeather® Becomes Official Weather Partner for Good360 to Enhance Disaster Resilience Nationwide
International, and UPS. Good360 is a registered 501(c)(3) organization. Media Contact AccuWeather: Gene Petriello, VP Corporate Communications [email protected] or
More news about: AccuWeather, Inc.
Sep 23, 2025, 09:15 ET LabConnect Partners with The Bracken Group to Expand Radiopharmaceutical Support Services
Scientific Consulting, and Data Integration and Transformation Services for analytically and logistically complex studies such as immuno-oncology, cell and gene therapies, and rare & orphan diseases. LabConnect's unique combination of state-of-the-art technology, world-class laboratories, easy access
More news about: LabConnect
Sep 23, 2025, 09:15 ET LabConnect Partners with The Bracken Group to Expand Radiopharmaceutical Support Services
Scientific Consulting, and Data Integration and Transformation Services for analytically and logistically complex studies such as immuno-oncology, cell and gene therapies, and rare & orphan diseases. LabConnect's unique combination of state-of-the-art technology, world-class laboratories, easy access
More news about: LabConnect
Sep 23, 2025, 09:15 ET Illumina advances personalized cancer care with new pharma development partnerships
Maryland Oncology Hematology. "The field is evolving rapidly, with new therapies better suited to patients with mutations in this once 'undruggable' gene. As the treatment landscape expands, including drugs that target the KRAS pathway, knowing a patient's KRAS status becomes essential to
More news about: Illumina, Inc.
Sep 23, 2025, 09:00 ET MEDIA ALERT: LEADERS GATHER AT GROUNDBREAKERS 2025
Gene Sykes, President and Chair of the Board of Directors, U.S. Olympic & Paralympic Committee;
More news about: Prologis, Inc.
Sep 23, 2025, 03:46 ET AI in Oncology For Analytical Solutions Market Size & Share to Surpass $8.86 Billion by 2035, Growing at a CAGR 21% | Vantage Market Research
2035.Gene Synthesis Market: The global Gene Synthesis Market is valued at USD 2.81 Billion in 2024 and is projected to reach a value of USD
More news about: Vantage Market Research
Sep 23, 2025, 03:21 ET Genomenon and Compass Bioinformatics Partner to Transform Genomic Diagnostics in the U.S. and Japan
innovative InheriNext platform for genetic disease diagnostics. The Mastermind FLEX data solution is a comprehensive data set that includes expertly curated gene and variant-level content with indexed variant-level information. This collaboration unites Compass Bioinformatics' AI-powered genomic analysis
More news about: Genomenon
Sep 23, 2025, 02:45 ET Mindray Unveils Project 2030 and Re-writes the Future of Women's Health Ultrasound at ISUOG
100 papers —those are the footprints of Project 2025. Moving forward, Mindray will continue to implement Project 2030. Gene Liang, General Manager, Medical Imaging of Mindray, emphasized, "We aim to continuously contribute to the development of basic ultrasound education
More news about: Mindray
Sep 23, 2025, 01:48 ET Mindray Unveils Project 2030 and Re-writes the Future of Women's Health Ultrasound at ISUOG
footprints of Project 2025. Moving forward, Mindray will continue to implement Project 2030. Gene Liang, General Manager, Medical Imaging of Mindray, emphasized, "We aim to continuously contribute to the development of basic ultrasound education
More news about: Mindray
Sep 22, 2025, 22:16 ET Kelun-Biotech's New Drug Application for Its Novel Next-generation Selective RET Inhibitor A400/EP0031 Accepted for Review by the NMPA for the Treatment of RET-fusion positive NSCLC
About RET-fusion positive NSCLC RET gene fusions represent one of the rare yet significant driver mutation types in NSCLC. In Chinese NSCLC patients, the incidence of RET gene fusions ranges from 1.4% to 2.5%[1]. Patients with RET fusions derive
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.